Abstract
Purpose:
Primates and rodents are used widely as animal models of glaucoma, but each has significant limitations. Researchers need additional animal models that closely resemble the relevant anatomy and pathologic features of the human disease to more quickly advance research. We validate a novel glaucoma animal model in tree shrews (Tupaia belangeri).
Methods:
Experimental glaucoma was induced in adult tree shrews (n = 8) by injecting 50 μL of a 25 mg/mL ferromagnetic bead solution into the anterior chamber. Beads were directed into the iridocorneal angle with a magnet to impede aqueous outflow. Animals were followed for 3 months with weekly IOP measurements and biweekly spectral domain optical coherence tomography (SD-OCT) images of the optic nerve head. Histopathology of the optic nerve and optic nerve axon counts were completed at the end of the study.
Results:
The 12-week average mean IOP was 22.7 ± 3.6 and 8.6 ± 2.9 mm Hg in the treated and control eyes, respectively. Longitudinal analysis showed significant retinal nerve fiber layer (RNFL) thinning throughout the study. Axon counts were significantly reduced (59.7%) in treated versus control eyes. SD-OCT imaging showed cupping and posterior displacement of the lamina cribrosa in glaucomatous eyes. RNFL thickness and optic nerve axon counts were reduced consistent with IOP elevation. Optic nerves demonstrated histopathology consistent with glaucomatous optic neuropathy.
Conclusions:
Tree shrews with experimental glaucoma show key pathologic characteristics of the human disease. The tree shrew model of glaucoma has the potential to help researchers accelerate our understanding of glaucoma pathophysiology.
Glaucoma is a leading cause of blindness worldwide,
1,2 yet we still are trying to develop a fundamental understanding of the underlying pathophysiologic mechanisms that lead to retinal ganglion cell (RGC) death. Development of animal models that accurately reflect the pathophysiology of human diseases is critical to advancing our understanding of the disease pathogenesis and its progression. Moreover, these models are instrumental in helping translate basic science discoveries, such as novel pharmacologic therapeutics, from in vitro, preclinical stages into human clinical trials.
The preponderance of evidence strongly suggests that the RGC axonal injury occurring within the lamina cribrosa is a critical component of glaucomatous injury.
3–9 This has led to increasing interest in understanding the mechanobiology of the optic nerve head (ONH) and the role of translaminar pressure differences in the development and progression of glaucoma. To understand these relationships, researchers must use animal models that most closely resemble the relevant human anatomy and develop key pathologic features of the human disease.
While nonhuman primates represent the most ideal animal model for certain types of glaucoma research due to their complex load-bearing collagenous lamina cribrosa resembling humans,
10–13 these models are costly and, thus, not applicable to larger studies required to evaluate new treatments. Alternatively, many researchers have chosen to use rat
14–20 or mouse
21–24 models of glaucoma in their research. Murine models have the advantage of allowing unparalleled study of the genetic and molecular pathobiology underlying glaucoma.
25–29 However, similar to rat models, mice lack a well-developed load-bearing ONH lamina cribrosa.
30,31 This structure is critical for investigating many of the biomechanical aspects of glaucoma, including, most critically, remodeling of the load-bearing connective tissues. In contrast, the tree shrew (
Tupaia belangeri) is a small mammal closely related to primates
32 that currently is used in vision research as an inducible myopia model.
33,34 Tree shrews are accessible and, most importantly, have a robust connective tissue lamina with horizontally-oriented laminar beams that insert into the peripapillary sclera and, thus, are load-bearing.
35 We validated a novel animal model of glaucoma in tree shrews by demonstrating a reliable method to chronically elevate IOP with resultant selective gradual loss of the RGC and retinal nerve fiber (RNFL) layers, histopathologic evidence of glaucomatous optic neuropathy, and remodeling of the load-bearing connective tissues of the ONHs consistent with human glaucoma.
All procedures were performed in compliance with the Association for Research in Vision and Ophthalmology Statement on the Use of Animals in Ophthalmic and Vision Research and were approved by the University of Alabama at Birmingham's Institutional Animal Care and Use Committee. Adult male and female tree shrews (n = 8) ranging from 1.7 to 7.7 years old (mean, 5.0 years) were used in this study. Animals were housed individually on a 12-hour light–dark cycle (lights on at 7:00 AM) with access to food and water ad libitum. For all procedures (induction of ocular hypertension, IOP measurements, and optical coherence tomography [OCT] imaging), animals were transported to the procedure rooms in their individual nest boxes. At the end of each procedure, animals were returned to their nest boxes and observed until fully mobile, at which point they were returned to their home cages. During the recovery period, nest boxes were warmed using a heating blanket.
Baseline in vivo SD-OCT imaging was performed 1 week before microsphere injection and biweekly for 12 weeks following each IOP assessment using the Spectralis SD-OCT (Heidelberg Engineering, Inc., Heidelberg, Germany). One drop 1% tropicamide and 2.5% phenylephrine was used to dilate the iris. A 20° × 15° raster scan through the ONH consisting of 37 high-resolution line B-Scans (9 scans/line averaged under ART Eye Tracking) in Enhanced Depth Imaging (EDI) mode, a 20° radial scan through the ONH consisting of 24 high-resolution B-Scans (18 scans/line averaged under ART Eye Tracking) in EDI mode, and the peripapillary RNFL thickness were measured using a circle scan at each time point. OCT images were analyzed for changes in peripapillary RNFL thickness, and the ONH line B-scans delineated for comparison to ONH sagittal reconstructions. All ONH images were exported in RAW (.vol) format and opened with the open source image processing program Fiji (ImageJ; National Institutes of Health [NIH], Bethesda, MD, USA) using the Open Heyex Raw plugin. Gamma then was adjusted to 0.35 and contrast enhanced 0.1%.
Baseline IOP and RNFL values between the magnetic microsphere injected and control eye were compared using an independent t-test. A repeated measures ANOVA then was used to determine whether microinjection of magnetic microspheres into the anterior chamber angle had a treatment-by-time effect on IOP and RNFL thickness. Where a time effect was found, an unpaired, 2-tailed t-test was used to compare individual time points between the treated and control groups. Total axon counts between the treated and control groups were compared using an independent 2-tailed t-test. All data are reported as mean ± SD. Significance was considered P < 0.05 for all experiments.
Similar to rodents, there is interanimal variability in the number of optic nerve axons. In studies comparing optic nerve axon counts to accumulated IOP (IOP × Days) and RNFL thickness, we normalized the axons counts by determining the percent of axons remaining in the experimental compared to the control eyes. Linear regression analysis was used to compare normalized 100% optic nerve axon counts versus accumulated IOP and versus change from baseline RNFL thickness.
The authors thank Thomas Norton, PhD, for his assistance in the early discussions on the development of this model as well as sharing his expertise in the use of tree shrews to model ophthalmic disease; and Jeff Messinger, BS, DC, for his assistance with aspects of the immunohistochemistry.
Supported in part by National Institutes of Health Grant R21EY026218 (BCS), the Glaucoma Research Foundation (CAG), the Eyesight Foundation of Alabama (CAG), and an unrestricted grant from Research to Prevent Blindness (CAG).
Disclosure: B.C. Samuels, None; J.T. Siegwart, None; W. Zhan, None; L. Hethcox, None; M. Chimento, None; R. Whitley, None; J.C. Downs, None; C.A. Girkin, None